{
    "Trade/Device Name(s)": [
        "StatStrip Glucose Hospital Meter System"
    ],
    "Submitter Information": "Nova Biomedical Corporation",
    "510(k) Number": "K232075",
    "Predicate Device Reference 510(k) Number(s)": [
        "K181043",
        "K060345",
        "K063821",
        "K132121",
        "K150281"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "PZI"
    ],
    "Summary Letter Date": "February 23, 2024",
    "Summary Letter Received Date": "October 26, 2023",
    "Submission Date": "October 26, 2023",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose Test System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Capillary finger stick whole blood",
        "Venous whole blood",
        "Arterial whole blood",
        "Neonatal arterial whole blood",
        "Neonatal heel stick whole blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "StatStrip Glucose Hospital Meter"
    ],
    "Method(s)/Technology(ies)": [
        "Electrochemical biosensor",
        "Enzyme, Amperometric Glucose Enzyme (Aspergillus sp., >1.0 IU)"
    ],
    "Methodologies": [
        "Enzymatic glucose measurement",
        "Amperometry"
    ],
    "Submission Type(s)": [
        "Analyzer",
        "Test Strip",
        "Control",
        "Linearity Solution",
        "Charging Station"
    ],
    "Document Summary": "FDA 510(k) summary for StatStrip Glucose Hospital Meter System, a next-generation ergonomic glucose analyzer with new OS for quantitative measurement of glucose in multiple whole blood specimen types in hospital and professional healthcare settings",
    "Indications for Use Summary": "Intended for point-of-care, in vitro diagnostic, multiple-patient quantitative determination of glucose in various whole blood specimens (capillary, venous, arterial, neonate arterial and heel stick) in all hospital and professional healthcare settings, including intensive care, excluding neonate cord blood and screening/diagnosis of diabetes mellitus, but indicated for determining dysglycemia.",
    "fda_folder": "Clinical Chemistry"
}